Search clinical trials for: Ado-Trastuzumab Emtansine

Total 134 results

Genentech, Inc.

No longer available

A Study of Trastuzumab-MCC-DM1 in Patients With HER2- Positive Locally Advanced or Metastatic Breast Cancer

Metastatic Breast Cancer

United States
Universidade Federal de Sergipe

Completed

IN-OFFICE TOOTH BLEACHING WITH 37% CARBAMIDE PEROXIDE

Tooth Sensitivity
Genentech, Inc.

Completed

Trastuzumab and Trastuzumab-MCC-DM1 Administered Intravenously and GDC-0941 Administered Orally to Patients With HER2-Positive Metastatic Breast Cancer Who Have Progressed on Previous Trastuzumab-Based Therapy

Metastatic Breast Cancer

United States
Hoffmann-La Roche

Completed

A Study of Trastuzumab Emtansine in Patients With HER2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic Function

Breast Cancer

United States, Canada, Spain, France, Italy
Hoffmann-La Roche

Completed

A Study of Trastuzumab Emtansine Versus Capecitabine + Lapatinib in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer (EMILIA)

Breast Cancer

France, Italy, Spain, Hong Kong, United States, Canada, Mexico, Denmark, Germany, Portugal, Taiwan, Switzerland, Bulgaria, Korea, Republic of, Singapore, United Kingdom, Slovenia, Bosnia and Herzegovina, Russian Federation, Br... and more
Hoffmann-La Roche

Completed

A Study of Trastuzumab Emtansine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-directed Therapy (TH3RESA)

Breast Cancer

Belgium, Israel, Spain, Sweden, United States, Switzerland, Russian Federation, Czech Republic, France, Canada, Germany, Korea, Republic of, Australia, Hungary, Thailand, United Kingdom, Italy, Brazil, Slovakia, Poland, India, Norway
Jenny C. Chang, MD
Genentech, Inc.; The Methodist Hospital Research Institute

Withdrawn

Trial of Neoadjuvant Trastuzumab Emtansine in Patients With HER2-Equivocal Breast Cancer (NATURE)

Breast Cancer

United States
Genentech, Inc.

Completed

A Study of Trastuzumab Emtansine, Paclitaxel, and Pertuzumab in Patients With HER2-Positive, Locally Advanced or Metastatic Breast Cancer

Metastatic Breast Cancer

United States
Genentech, Inc.

Completed

A Study of Trastuzumab-MCC-DM1 Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer Who Have Previously Received a Trastuzumab-Containing Regimen

Metastatic Breast Cancer
ImmunoGen, Inc.

Completed

IMGN901 in Combination With Lenalidomide and Dexamethasone

Multiple Myeloma

United States
Hoffmann-La Roche

Completed

A Study of Trastuzumab Emtansine (T-DM1) Sequentially With Anthracycline-based Chemotherapy, as Adjuvant or Neoadjuvant Therapy for Patients With Early Stage Herceptin (HER)2-positive Breast Cancer

Breast Cancer

Spain, United States, France, Germany, Belgium, Korea, Republic of, Italy, Russian Federation
Hoffmann-La Roche

Completed

A Study of the Efficacy and Safety of Trastuzumab Emtansine (Trastuzumab-MCC-DM1) vs. Trastuzumab (Herceptin®) and Docetaxel (Taxotere®) in Patients With Metastatic HER2-positive Breast Cancer Who Have Not Received Prior Chemotherapy for Metastatic Disease

Breast Cancer
Hoffmann-La Roche
Roche Pharma AG

Completed

A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1, T-DM1) in Combination With Pertuzumab Administered to Patients With Human Epidermal Growth Factor Receptor-2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer Who Have Previously Received Trastuzumab

Metastatic Breast Cancer

Italy, Spain, Canada, United States, Belgium, France, Germany
Genentech, Inc.

Completed

Corrected QT Interval Effects of Trastuzumab Emtansine (T-DM1) in Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer and the Safety and Tolerability of Combined T-DM1 and Pertuzumab in Patients With Early Disease Progression

Metastatic Breast Cancer
Genentech, Inc.

Completed

A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1) Administered Intravenously to Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer

Metastatic Breast Cancer

United States
The First Affiliated Hospital with Nanjing Medical...

Recruiting

Tyrosine Kinase Inhibitors (TKIs) in Trastuzumab Emtansine (T-DM1) Resistant HER2-positive Metastatic Breast Cancer: A Real-world Study

Breast Cancer

China
Seagen Inc.

Recruiting

A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer

HER2-positive Breast Cancer

United States, Australia, Austria, Belgium, Canada, China, Denmark, France, Germany, Israel, Italy, Japan, Korea, Republic of, Netherlands, Singapore, Spain, Sweden, Switzerland, Taiwan, United Kingdom
Hoffmann-La Roche
Latin American Cooperative Oncology Group

Active, not recruiting

A Study to Describe the Diagnosis, Anti-Cancer Treatment and Clinical Outcome in Patients With Newly Diagnosed Breast Cancer in Latin America

Breast Cancer

Colombia, Guatemala, Argentina, Brazil, Chile, Cuba, Mexico, Peru, Uruguay, Dominican Republic
Daiichi Sankyo, Inc.
AstraZeneca; Daiichi Sankyo Co., Ltd.

Active, not recruiting

A Study of DS-8201a in Metastatic Breast Cancer Previously Treated With Trastuzumab Emtansine (T-DM1)

Breast Cancer

United States, Spain, Italy, Korea, Republic of, Belgium, France, Japan, United Kingdom, Canada
Bial - Portela C S.A.

Active, not recruiting

eArly levoDopa With Opicapone in Parkinson's paTients wIth motOr fluctuatioNs. (ADOPTION)

Parkinson Disease

Spain, Italy, Portugal, Germany, United Kingdom
West German Study Group
Roche Pharma AG

Active, not recruiting

A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Trastuzumab Emtansine (T-DM1) With or Without Standard Endocrine Therapy vs. Trastuzumab With Standard Endocrine Therapy Given for Twelve Weeks in Patients With Operable HER2+/HR+ Breast Cancer Within the ADAPT Protocol. (ADAPT; T-DM1)

Breast Cancer

Germany
Consorzio Oncotech

Completed

Liquid Biopsy: Intercepting Mutational Trajectories of HER2 (Human Epidermal Growth Factor Receptor 2) Breast Cancer (GIM21 Trial) (GIM21)

Metastatic Breast Cancer

Italy
NSABP Foundation Inc
Puma Biotechnology, Inc.

Completed

A Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DM1) With Neratinib in Women With Metastatic HER2-Positive Breast Cancer

Breast Cancer

United States
Alberto Espay, MD, MSc
Lundbeck LLC

Completed

Lundbeck TOMs Orthostatic Hypotension

Orthostatic Hypotension | Idiopathic Parkinson Disease

United States
University of Texas Southwestern Medical Center

Terminated

Averting Complications of Proton Pump Inhibitor Therapy by Effervescent Calcium Magnesium Citrate

Osteoporosis | Hypomagnesemia

United States
Seagen Inc.

Completed

A Study of Tucatinib (ONT-380) Combined With Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2+ Breast Cancer

HER2 Positive Breast Cancers

United States, Canada
Thomas Hatschek

Active, not recruiting

Neoadjuvant Response-guided Treatment of HER2 Positive Breast Cancer (PREDIX HER2)

Early-Stage Breast Carcinoma | HER-2 Positive Breast Cancer

Sweden
Universidade Federal do Para

Completed

Effect of Glutaraldehyde on Dentin Hypersensitivity After Non-surgical Periodontal Treatment

Dentin Sensitivity

Brazil
BELEN RUIZ-ANTORAN

Completed

Outcomes Of The Spanish Cohort Of Early Access To Pertuzumab And Trastuzumab Emtansine (KNOWHER)

Breast Neoplasms

Spain
Ohio State University Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Taste Acceptability of Tomato-Soy-Arugula Seed Beverages in Men With Prostate Cancer

Prostate Carcinoma

United States
Institut Curie

Completed

Validity of HER2-amplified Circulating Tumor Cells to Select Metastatic Breast Cancer Considered HER2-negative for Trastuzumab-emtansine (T-DM1) Treatment.

Metastatic Breast Cancer, HER2 Negative Primary Tumor

France
Merrimack Pharmaceuticals

Terminated

MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients (HERMIONE)

Breast Cancer | HER2 Positive Breast Cancer

Spain, United States, Italy, France, Canada, Belgium, Austria, Germany, Czech Republic
Fundación FLS de Lucha Contra el Sida, las Enfermedades...

Completed

Multicentre Study To Assess Changes In Bone Mineral Density Of The Switch From Protease Inhibitors To Dolutegravir In HIV-1-Infected Subjects With Low Bone Mineral Density

HIV-1 Infection

Spain
Gilead Sciences

Completed

Part A: Drug Interaction Study of Sofosbuvir and Antiretroviral Therapy (ART) Combinations in HIV and Hepatitis C Virus (HCV) Co-infected Patients. Part B: Efficacy and Safety of Sofosbuvir for 12 Weeks in HIV/HCV Co-infected Patients.

Hepatitis C | HIV

Puerto Rico

3

Subscribe